HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach

Regulatory Toxicology and Pharmacology

Volumn 75, Issue , 2016, Pages 72-80

  Lebrec, H ^a   Brennan, F R ^b   Haggerty, H ^c   Herzyk, D ^d   Kamperschroer, C ^e   Maier, C C ^f   Ponce, R ^a   Preston, B D ^a   Weinstock, D ^g   Mellon, R D ^h  

^a AMGEN INC   (United States)

^b UCB PHARMA   (Belgium)

^c BRISTOL MYERS SQUIBB   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e PFIZER INC   (United States)

^f GLAXOSMITHKLINE   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^h CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cancer; Carcinogenicity; Immunomodulation; Immunosuppression; Immunotoxicity; Immunotoxicology; Risk assessment

Indexed keywords

GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOIMMUNITY; CANCER RISK; CARCINOGENESIS; CELL STIMULATION; CHRONIC B CELL STIMULATION; CHRONIC DRUG ADMINISTRATION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR IMMUNITY; TUMOR IMMUNOEDITING; TUMOR PROMOTION; TUMOR VIRUS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; IMMUNOLOGY; LEGISLATION AND JURISPRUDENCE; NEOPLASMS;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; RISK ASSESSMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84953727196     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.12.018     Document Type: Article

References (75)

1. Ablashi D.V., Chatlynne L.G., Whitman J.E., Cesarman E. Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin. Microbiol. Rev. 2002, 15(3):439-464.
2. Albertson T.M., Ogawa M., Bugni J.M., Hays L.E., Chen Y., Wang Y., Treuting P.M., Heddle J.A., Goldsby R.E., Preston B.D. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(40):17101-17104.
3. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., Catrina A.I., Rosenquist R., Feltelius N., Sundstrom C., Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006, 54(3):692-701.
4. Biron C.A., Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 2001, 13(4):458-464.
5. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-2285.
6. Bongartz T., Warren F.C., Mines D., Matteson E.L., Abrams K.R., Sutton A.J. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 2009, 68(7):1177-1183.
7. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 2002, 55(4):244-265.
8. Brehm M.A., Wiles M.V., Greiner D.L., Shultz L.D. Generation of improved humanized mouse models for human infectious diseases. J. Immunol. Methods 2014, 410:3-17.
9. Bugelski P.J., Volk A., Walker M.R., Krayer J.H., Martin P., Descotes J. Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int. J. Toxicol. 2010, 29(5):435-466.
10. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 1975, 72(9):3666-3670.
11. Celiksoy M.H., Topal E., Yildiran A. Comparison of major lymphocyte subpopulations and recent thymic emigrants in patients with ataxia telangiectasia and age-matched healthy groups. Allergol. Immunopathol. Madr. 2014, 43(5):477-481.
12. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
13. Cunningham-Rundles C., Cooper D.L., Duffy T.P., Strauchen J. Lymphomas of mucosal-associated lymphoid tissue in common variable immunodeficiency. Am. J. Hematol. 2002, 69:171-178.
14. de Visser K.E., Korets L.V., Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7(5):411-423.
15. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3(11):991-998.
16. DuPage M., Cheung A.F., Mazumdar C., Winslow M.M., Bronson R., Schmidt L.M., Crowley D., Chen J., Jacks T. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011, 19(1):72-85.
17. DuPage M., Jacks T. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr. Opin. Immunol. 2013, 25(2):192-199.
18. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482(7385):405-409.
19. Egberts J.H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., Kettler B., von Forstner C., Kneitz C., Tepel J., Adam D., Wajant H., Kalthoff H., Trauzold A. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008, 68(5):1443-1450.
20. Engels E.A., Biggar R.J., Hall H.I., Cross H., Crutchfield A., Finch J.L., Grigg R., Hylton T., Pawlish K.S., McNeel T.S., Goedert J.J. Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer 2008, 123(1):187-194.
21. Federico A., Morgillo F., Tuccillo C., Ciardiello F., Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 2007, 121(11):2381-2386.
22. Food and Drug Administration Biologics Licensing Application Review - Alefacept 2002, Available online at:. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm086014.pdf.
23. Food and Drug Administration International Conference on Harmonization; Proposed Change for Comments 2013, Federal Register. Docket No. FDA-2013-N-0222.
24. Fujiwara S., Imadome K., Takei M. Modeling EBV infection and pathogenesis in new-generation humanized mice. Exp. Mol. Med. 2015, 47:e135.
25. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoue F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
26. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., Lugli A., Zlobec I., Hartmann A., Bifulco C., Nagtegaal I.D., Palmqvist R., Masucci G.V., Botti G., Tatangelo F., Delrio P., Maio M., Laghi L., Grizzi F., Asslaber M., D'Arrigo C., Vidal-Vanaclocha F., Zavadova E., Chouchane L., Ohashi P.S., Hafezi-Bakhtiari S., Wouters B.G., Roehrl M., Nguyen L., Kawakami Y., Hazama S., Okuno K., Ogino S., Gibbs P., Waring P., Sato N., Torigoe T., Itoh K., Patel P.S., Shukla S.N., Wang Y., Kopetz S., Sinicrope F.A., Scripcariu V., Ascierto P.A., Marincola F.M., Fox B.A., Pages F. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 2014, 232(2):199-209.
27. Garbe A.I., Vermeer B., Gamrekelashvili J., von Wasielewski R., Greten F.R., Westendorf A.M., Buer J., Schmid R.M., Manns M.P., Korangy F., Greten T.F. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res. 2006, 66(1):508-516.
28. Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., Olsson H., Jacobsson L.T. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 2005, 64(5):699-703.
29. Gompels M.M., Hodges E., Lock R.J., Angus B., White H., Larkin A., Chapel H.M., Spikett G.P., Misbach S.A., Smith J.L., Associated Study Group Lymphoproliferative disease in antibody deficiency: a multi-centre study. Clin. Exp. Immunol. 2003, 134:314-320.
30. Green S., Dobrjansky A., Carswell E.A., Kassel R.L., Old L.J., Fiore N., Schwartz M.K. Partial purification of a serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 1976, 73(2):381-385.
31. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370(9581):59-67.
32. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 2001, 19:65-91.
33. Gujer C., Chatterjee B., Landtwing V., Raykova A., McHugh D., Munz C. Animal models of Epstein Barr virus infection. Curr. Opin. Virol. 2015, 13:6-10.
34. Hutto D. Opportunistic infections in non-human primates exposed to immunomodulatory biotherapeutics: considerations and case examples. J. Immunotoxicol. 2010, 7(2):120-127.
35. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals S1A 1995.
36. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Testing for Carcininogenicity of Pharmaceuticals S1B 1997.
37. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals S6(R1) 2011.
38. Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000, 356:1795-1799.
39. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Concept Paper: S1: Rodent Carcinogenicity Studies for Human Pharmaceuticals 2012.
40. Jacobs A.C. Carcinogenicity Studies. Toxicological Testing Handbook: Principles, Applications, and Data Interpretation 2006, 249-264. Informa Healthcare, New York. D. Jacobsom-Kram, K.A. Keller (Eds.).
41. Kalha I., Sellin J.H. Common variable immunodeficiency and the gastrointestinal tract. Curr. Gastroenterol. Rep. 2004, 6(5):377-383.
42. Kasiske B.L., Snyder J.J., Gilbertson D.T., Wang C. Cancer after kidney transplantation in the United States. Am. J. Transpl. 2004, 4(6):905-913.
43. Kawabata T., Weaver J., Thomas D., Rowe M., Wang F., Kamperschroer C., Haggerty H. Summary of roundtable discussion meeting: non-human primates to assess risk of EBV-related lymphomas in humans. J. Immunotoxicol. 2011, 19(1):121-127.
44. Kidd B.A., Peters L.A., Schadt E.E., Dudleu J.T. Unifying immunology with informatics and multiscale biology. Nat. Immunol. 2014, 15(2):118-127.
45. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer 2005, 5(4):251-262.
46. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., Biedrzycki B., Donehower R.C., Zaheer A., Fisher G.A., Crocenzi T.S., Lee J.J., Duffy S.M., Goldberg R.M., de la Chapelle A., Koshiji M., Bhaijee F., Huebner T., Hruban R.H., Wood L.D., Cuka N., Pardoll D.M., Papadopoulos N., Kinzler K.W., Zhou S., Cornish T.C., Taube J.M., Anders R.A., Eshleman J.R., Vogelstein B., Diaz L.A. PD-1 Blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015, 372(26):2509-2520.
47. Lebrec H., Horner M.J., Gorski K.S., Tsuji W., Xia D., Pan W.J., Means G., Pietz G., Li N., Retter M., Shaffer K., Patel N., Narayanan P.K., Butz E.A. Homeostasis of human NK cells is not IL-15 dependent. J. Immunol. 2013, 191(11):5551-5558.
48. Lebrec H., Ponce R., Preston B.D., Iles J., Born T.L., Hooper M. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr. Med. Res. Opin. 2015, 31(3):557-574.
49. Malmgaard L. Induction and regulation of IFNs during viral infections. J. Interferon Cytokine Res. 2004, 24(8):439-454.
50. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444.
51. McGilvray R.W., Eagle R.A., Watson N.F.S., Al-Attar A., Ball G., Jafferji I., Trowsdale J., Durrant L.G. NKG2D Ligand expression in human colorectal cancer reveals associations with prognosis and evidence of immunoediting. Clin. Cancer Res. 2009, 15(22):6993-7002.
52. Mercer L.K., Davies R., Galloway J.B., Low A., Lunt M., Dixon W.G., Watson K.D., Symmons D.P., Hyrich K.L., British Society for Rheumatology Biologics Register Control Centre, C Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatol. Oxf. 2013, 52(1):91-98.
53. Miceli-Richard C., Gestermann N., Amiel C., Sellam J., Ittah M., Pavy S., Urrutia A., Girauld I., Carcelain G., Venet A., Mariette X. Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies. Arthritis Res. Ther. 2009, 11(3):R77.
54. Mittal D., Gubin M.M., Schreiber R.D., Smyth M.J. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 2014, 27:16-25.
55. Nicot C. Current views in HTLV-1-associated adult T cell leukemia/lymphoma. Am. J. Hematol. 2005, 78(3):232-239.
56. Orange J.S. Natural killer cell deficiency. J. Allergy Clin. Immunol. 2013, 132(3):515-526.
57. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353(25):2654-2666.
58. Penn I. Posttransplant malignancies. Transpl. Proc. 1999, 31(1-2):1260-1262.
59. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000, 23(2):101-113.
60. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contribution of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006, 45(4):529-538.
61. Piselli P., Busnach G., Fratino L., Citterio F., Ettorre G.M., De Paoli P., Serraino D., Immunosuppression Cancer Study, G. De novo malignancies after organ transplantation: focus on viral infections. Curr. Mol. Med. 2013, 13(7):1217-1227.
62. Ponce R.A., Gelzleichter T., Haggerty H.G., Heidel S., Holdren M.S., Lebrec H., Mellon R.D., Pallardy M. Immunomodulation and lymphoma in humans. J. Immunotoxicol. 2014, 11(1):1-12.
63. Pozadzides J.V., Pro B. Hepatosplenic T-cell lymphoma and TNF-alpha inhibitors. Expert Rev. Hematol. 2009, 2(6):611-614.
64. Preston B.D., Albertson T.M., Herr A.J. DNA replication fidelity and cancer. Semin. Cancer Biol. 2010, 20(5):281-293.
65. Reilly T.P., Abbott M., Golovkina T., Proctor J., Case L., Comereski C., Fang H., Wells S., Freebern W., Frantz J., Durham S., Haggerty H.G. Role of immunomodulation by the selective costimulation modulator, Abatacept, in Mouse Mammary Tumor Virus (MMTV)-initiated tumors. Toxicol. 2005, 90:50.
66. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348(6230):69-74.
67. Sistare F.D., Morton D., Alden C., Christensen J., Keller D., Jonghe S.D., Storer R.D., Reddy M.V., Kraynak A., Trela B., Bienvenu J.G., Bjurstrom S., Bosmans V., Brewster D., Colman K., Dominick M., Evans J., Hailey J.R., Kinter L., Liu M., Mahrt C., Marien D., Myer J., Perry R., Potenta D., Roth A., Sherratt P., Singer T., Slim R., Soper K., Fransson-Steen R., Stoltz J., Turner O., Turnquist S., van Heerden M., Woicke J., DeGeorge J.J. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol. Pathol. 2011, 39(4):716-744.
68. Solomon D.H., Kremer J.M., Fisher M., Curtis J.R., Furer V., Harrold L.R., Hochberg M.C., Reed G., Tsao P., Greenberg J.D. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin. Arthritis Rheum. 2014, 43(4):489-497.
69. Stone J.H., Holbrook J.T., Marriott M.A., Tibbs A.K., Sejismundo L.P., Min Y.I., Specks U., Merkel P.A., Spiera R., Davis J.C., St Clair E.W., McCune W.J., Ytterberg S.R., Allen N.B., Hoffman G.S., Wegener's Granulomatosis Etanercept Trial Research, G Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006, 54(5):1608-1618.
70. Thomas E., Brewster D.H., Black R.J., Macfarlane G.J. Risk of malignancy among patients with rheumatic conditions. Int. J. Cancer 2000, 88:497-502.
71. Uittamo J., Siikala E., Kaihovaara P., Salaspuro M., Rautemaa R. Chronic candidosis and oral cancer in APECED-patients: production of carcinogenic acetaldehyde from glucose and ethanol by Candida albicans. Int. J. Cancer 2009, 124(3):754-756.
72. van Gool I.C., Eggink F.A., Freeman-Mills L., Stelloo E., Marchi E., de Bruyn M., Palles C., Nout R.A., de Kroon C.D., Osse E.M., Klenerman P., Creutzberg C.L., Tomlinson I.P., Smit V.T., Nijman H.W., Bosse T., Church D.N. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin. Cancer Res. 2015, 21(14):3347-3355.
73. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235-271.
74. Weinblatt M.E., Moreland L.W., Westhovens R., Cohen R.B., Kelly S.M., Khan N., Pappu R., Delaet I., Luo A., Gujrathi S., Hochberg M.C. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J. Rheumatol. 2014, 40:787-797.
75. Wolfe F., Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007, 56(5):1433-1439.